During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice Semiconductor and Cognex during the quarter. In addition to Modine Manufacturing, we ended our investment campaigns in Monolithic Power Systems and Tradeweb Markets.
Needham reportedly cut its Veracyte price target by $23 per share after the Company's November 4, 2026 outlook reset on its Decipher Prostate test. An investigation into potential securities law violations is underway on behalf of VCYT shareholders who lost money.
Veracyte is rated Hold, as its valuation premium has vanished, but growth prospects have weakened, especially for Decipher prostate cancer testing. Decipher's test volume growth is slowing sharply, with management now planning for a 40% lower annual increase versus prior years. VCYT trades at 2.87x forward sales and 12.95x earnings, below sector medians, yet consensus expects a 19.38% EPS decline in 2027.
Veracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good afternoon.
Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk
LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.
Shares of Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) saw unusually-high trading volume on Friday. 1,904,920 shares traded hands during trading, an increase of 57% from the average daily volume of 1,211,597 shares. The stock last traded at $24.31 and had previously closed at $24.00. More Veracyte News Here are the key news stories impacting
VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
/PRNewswire/ -- A $100 million buyback authorization and $151.8 million in third-quarter revenue did not hold up Veracyte, Inc. (NASDAQ: VCYT) shares, which
Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel Lauren Timmins - Jefferies LLC, Research Division Mason Carrico - Stephens Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Michael Matson - Needham & Company, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2026 Financial Results Conference Call.